Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab and ulcerative colitis.

Mario Cottone1, Filippo Mocciaro, Irene Modesto

  • 1Università di Palermo, Istituto di Medicina Generale e Pneumologia, Via Trabucco 180, Palermo, Italy. dickens@tin.it

Expert Opinion on Biological Therapy
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).

United European gastroenterology journal·2026
Same author

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

A Novel Endoscopic Strategy for Addressing Complex Gastrointestinal Defects via the X-Tack System: A Case Series With Videos.

DEN open·2025
Same author

Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic Review.

Inflammatory bowel diseases·2025
Same author

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Journal of Crohn's & colitis·2025
Same author

Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025

Infliximab shows promise for severe ulcerative colitis (UC) patients, particularly those refractory to steroids, potentially sparing colectomy. However, long-term benefits require further investigation, especially in pediatric cases.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Tumour necrosis factor (TNF)-alpha is a key inflammatory cytokine in inflammatory bowel disease (IBD).
  • While distinct cytokine profiles exist for ulcerative colitis (UC) and Crohn's disease (CD), TNF-alpha plays a significant role in UC.
  • Infliximab, a monoclonal antibody targeting TNF-alpha, has been investigated for UC therapy.

Purpose of the Study:

  • To evaluate the efficacy of infliximab in various clinical settings of ulcerative colitis (UC) in adults and children.
  • To assess infliximab's role in moderate-severe steroid-dependent UC, severe refractory UC, active non-steroid-refractory UC, resistant pouchitis, and maintenance therapy.

Main Methods:

  • Review of randomized controlled trials (RCTs) evaluating infliximab in adult and pediatric UC patients.

Related Experiment Videos

  • Analysis of treatment outcomes in different UC patient subgroups based on steroid dependency and prior therapy.

    • Main Results:

    • In adults, infliximab appears effective in severe steroid-refractory UC, potentially avoiding colectomy, with statistically significant short-term remission induction.
    • Long-term benefits in adults were not clinically impressive compared to placebo, despite statistical significance.
    • Limited RCT data for children prevents definitive conclusions, though open studies show promise in steroid-refractory UC.

    Conclusions:

    • Infliximab demonstrates activity in severe steroid-refractory UC in adults, offering a potential alternative to colectomy.
    • Further research with stringent criteria is needed to define infliximab's role in various UC severities and maintenance therapy.
    • Efficacy in pediatric UC requires more robust evidence from randomized controlled trials.